SelectScience
Join Free
Accelerating Science
NewsLife Sciences

Avacta enters into collaboration and option agreement with ADC Therapeutics

Avacta Group plc

New collaboration to focus on developing potent Affimer-drug conjugates

10 Oct 2019
Arran Tabary-Davies
Microbiologist

Industry news

Avacta Group plc, a biotechnology company developing novel cancer immunotherapies based on its proprietary Affimer® platform, has announced that it has entered a collaboration and option agreement with ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The agreement is to develop Affimer-drug conjugates combining Avacta’s Affimer technology with ADC Therapeutics’ pyrrolobenzodiazepine (PBD)-based warhead and linker technologies.

As part of the multi-target collaboration Avacta will generate and optimize Affimer binders against three undisclosed cancer targets and provide these to ADC Therapeutics to target its proprietary cytotoxic warheads (PBDs) to the site of the tumor. ADC Therapeutics will carry out pre-clinical research and development programmes to evaluate each of the Affimer-drug conjugates with a view to generating clinical candidates.

The commercial agreement between the two companies provides ADC Therapeutics with options, on a target by target basis, to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization.

Under the terms of the agreement, ADC Therapeutics will cover all Avacta’s costs during the collaboration. Upon ADC Therapeutics entering into each of the commercialization licenses and successfully bringing new Affimer-drug conjugates to market, Avacta will receive option fees, development and commercialization milestones, as well as a single-digit royalty on sales. Further financial details are not disclosed.

Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: “I am delighted to have established this collaboration with ADC Therapeutics to develop drug conjugates that harness the benefits of Affimer proteins to selectively and efficiently target ADC Therapeutics’ PBD drugs to the site of the tumour. We are very excited about the potential of this collaboration to develop breakthrough oncology treatments, and about its considerable commercial value to Avacta. We look forward to working closely with the ADC Therapeutics team to generate new Affimer-drug conjugates and advance these promising cancer treatments into the clinic.”

Register for your free SelectScience membership today to receive the latest editorial articles and technology news direct to your inbox>>

Links

Avacta Group plc

Tags

AntibodiesAntibodies are used in techniques such as confocal and fluorescence microscopy, flow cytometry, ELISA, ELISPOT, immunohistochemistry, western blotting and immunopreciptation. Select specific antigen reactivity, high specific affinity, low non-specific binding, monoclonal or polyclonal, primary or secondary antibodies and associated conjugates such as an enzyme or dye for visualization.ImmunologyImmunological techniques measure and characterize immune responses. Immunology kits and analysis systems often use techniques such as ELISA, radioimmunoassay (RIA) and immunodiffusion assays, Immunohistochemistry, and flow cytometry. Immunologists use equipment such as flow Cytometers, plate readers, plate washers and fluorescent microscopes.Cellular PathologyCellular Pathology deals with the microscopic analysis of tissue samples and cells. Sample preparation and processing includes fixation, staining, sectioning and slide mounting, using equipment such microtomes and cryostats. In choosing immunohistochemistry and immunocytochemistry kits, consider chromogens, staining method, antibodies, microscopes and imaging.Clinical TrialsClinical Trials, an essential part of drug discovery process, assess the safety and effectiveness of a new medication or device in the pharmaceutical industry. Clinical Trials are a phased process (Phase 0, Phase I, Phase II, Phase III and Phase IV) which begins after initial preclinical testing.ImmunotherapyImmunotherapy is a treatment approach that utilizes the body�s immune system to fight diseases, especially cancer. It includes therapies such as monoclonal antibodies, checkpoint inhibitors, and CAR-T cell therapy. Immunotherapy is a rapidly growing area of research in oncology and autoimmune diseases. Browse our peer-reviewed product directory to find the best immunotherapy tools, compare products, check reviews, and get pricing directly from manufacturers.Antibody ProductionAntibody production is essential for a wide range of applications in biochemistry and immunology. Ensuring high-quality monoclonal and polyclonal antibodies are produced is key. Explore antibody production tools in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Cancer ResearchAlthough cancer is often referred to as a single condition, it actually consists of more than 100 different diseases. Microscopy, mass spectrometry, high throughput sequencing and flow cytometry are some of the most common techniques employed in cancer research labs.

Related articles

Avacta enters into collaboration and option agreement with ADC Therapeutics